(Tromsø, 25 September 2017) Biotec Pharmacon ASA's ("Biotec", OSE: BIOTEC)
subsidiary Biotec BetaGlucans has today signed a supply agreement for M-GlucanT
to a customer within the pet food segment
Deliveries under the agreement will commence in the fourth quarter of 2017 and
run through 2020. Expected revenues for the contract period is around NOK 3
million depending on customer sales of pet food containing M-Glucan as an
ingredient.
This supply agreement represents the first supply agreement outside of the
marine farmed food segment and is part of Biotec BetaGlucans strategy to expand
supply of M-Glucan into other business segments.
"We're really pleased to sign this agreement as it represents a new market
segment and opportunities for M-Glucan. Even though the contract is relative
small in volume, it will be important as a reference for further agreements in
this segment, says Biotec Pharmacon's CFO Børge Sørvoll.
For more information, please contact:
Børge Sørvoll,
CFO
tel +47 952 90 187
borge.sorvoll@biotec.no
About Biotec Pharmacon ASA:
Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and
ArcticZymes AS. ArcticZymes develops, produces and markets enzymes of marine
origin used in molecular DNA technologies and diagnostics, representing growth
markets where rapid technological developments are creating a strong demand for
new and improved enzymes.